Ask AI
ProCE Banner Activity

Guideline-Concordant Bladder Cancer Care in Community Practice: Team-Based Strategies for MIBC and First-line la/mUC

Slideset

Evolving evidence and treatment options have raised important questions about how to coordinate care for patients with muscle-invasive bladder cancer and first-line locally advanced or metastatic urothelial carcinoma, particularly in rural settings. This downloadable slideset reviews current evidence and guideline recommendations for perioperative and bladder-preserving treatment, first-line therapy and treatment sequencing, biomarker testing, and toxicity management. The slides also inform how multidisciplinary coordination, patient goals, and barriers such as travel burden can affect practical, patient-centered care.

Released: November 19, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by educational grants from Merck Sharp & Dohme LLC and Pfizer Inc.

Merck Sharp & Dohme LLC

Pfizer Inc.

Target Audience

This activity is intended for surgical urologists, urologists, uro-oncologists, medical oncologists, radiation oncologists, nurse practitioners, physician associates, nurses, pharmacists, navigators, and other MDT HCPs responsible for treatment decisions, treatment coordination, adverse-event monitoring, and supportive care for patients with MIBC and first-line la/mUC in rural and community practice settings.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess patient-, disease-, and practice-level factors that influence MIBC care planning, including cisplatin eligibility, surgical fitness, renal function, baseline neuropathy, frailty, nodal status, bladder-preservation candidacy, caregiver support, travel burden, and patient goals

  • Evaluate perioperative, adjuvant, immunotherapy-based, and ADC-based treatment strategies for patients with MIBC and first-line la/mUC based on efficacy, safety, eligibility, sequencing implications, monitoring needs, and access-to-care considerations

  • Integrate biomarker and risk-stratification information into multidisciplinary treatment planning, including FGFR3 alterations, HER2 expression, MSI/MMR status, tissue adequacy, repeat biopsy considerations, and appropriate interpretation of emerging ctDNA/MRD data

  • Implement multidisciplinary, patient-centered strategies to improve urology–medical oncology–radiation oncology coordination, recognize and mitigate immune-related and ADC-associated adverse events, support APP/nurse-led toxicity triage, and strengthen shared decision-making with patients and caregivers

Additional Disclosures

Generative artificial intelligence (AI) tools were used for revising or refining educational content, and drafting assessment question(s) and/or rationale(s). All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.